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During development, the interaction of stem cell factor
(SCF) with its receptor, KIT, is critical for the survival of
melanocytes.Limited in vivohumanstudieshave suggested
a possible activating role of SCF on adult human melano-
cytes. In order to study the impact of this pathway on
normal melanocyte homeostasis, human skin xenografts
were treated with serial injections of recombinant human
SCF or a KIT-inhibitory antibody (K44.2). On histologic
evaluation, SCF injection increased, whereas KIT inhibi-
tiondecreased thenumber, size, anddendricity ofmelano-
cytes. Immunohistochemical expression of melanocyte
differentiation antigens, including tyrosinase-related-
The regulatory processes that maintain the number andactivity of melanocytes within normal human skin arenot well understood. Disorders of this regulatory processmay result in melanocyte loss (as in graying hair, vitiligo,or idiopathic guttate hypomelanosis) or proliferation (as
in melasma, melanocytic nevus, or melanoma). Melanocytes of human
skin normally survive within a cellular milieu that conditions their
existence. Keratinocytes, in particular, produce many factors that
potentiate the survival and growth of melanocytes (Gordon et al, 1989;
Donatien et al, 1993; Herlyn and Shih, 1994; Hara et al, 1995). One
intriguing pathway for such regulatory control is the interaction of
keratinocyte-derived stem cell factor (SCF, also known as mast cell
growth factor, KIT ligand, and steel factor) with its receptor, KIT,
present on the surface of the melanocyte. The gene for SCF is located
on chromosome 12 and is variably spliced, yielding two mRNA
products encoding membrane-bound proteins of 248 amino acids and
220 amino acids (Morstyn et al, 1994). KIT is a 145 kDa transmembrane
class III tyrosine kinase receptor encoded on chromosome 4 (Yarden
et al, 1987; Vandenbark et al, 1992). Upon binding to SCF, KIT
dimerizes and autophosphorylates (Blume-Jensen et al, 1991) and
activates downstream pathways that may include PI3K, PLCγ, MAP2K,
Raf1, and JAK2 (Yee et al, 1993; Weiler et al, 1996).
The SCF/KIT pathway is critical for melanocytic, reproductive,
and hematologic development. Homozygous, severe defects in either
SCF or the KIT receptor give rise to mice that are white-coated,
sterile, anemic, and often nonviable (Bernstein et al, 1991; Halaban
and Moellmann, 1993; Morstyn et al, 1994). It appears that during
development of these mutants cutaneous melanocytes do not survive
and therefore fail to pigment hair. The crucial role of the SCF/
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protein-1 and gp100/pmel17, was markedly increased by
treatment with SCF, and decreased by K44.2 treatment.
The number of Ki67-positive melanocytes was increased
in the SCF-treated tissue, suggesting a direct proliferative
effect of SCF; conversely, treatment with K44.2 resulted
in melanocyte loss, which did not appear reversible with
prolonged treatment. These findings demonstrate that the
SCF/KIT pathway remains critical in adult human skin,
and that pharmacologic modulation of this single pathway
can control cutaneous melanocyte homeostasis. Key words:
HMB-45/K44.2/mast cell growth factor/xenograft. J Invest
Dermatol 111:233–238, 1998
KIT pathway for developing murine melanocytes has been further
demonstrated through experiments utilizing an anti-SCF antibody,
ACK2, that specifically blocks its activation of Kit (Nishikawa et al,
1991; Okura et al, 1995; Yoshida et al, 1996). The SCF-KIT pathway
is also critical for the development of human melanocytes. Patients
with piebaldism, a disorder presenting at birth with amelanotic patches
on ventral and/or acral skin surfaces, but apparently lacking detectable
defects in germ cells or the hematologic system, are heterozygous for
c-KIT mutations (Giebel and Spritz, 1991; Spritz et al, 1992; Ezoe et al,
1995). These findings demonstrate that, at least at the developmental
level, the SCF/KIT pathway is of critical importance to melanocyte
survival.
We have demonstrated previously that SCF injection causes activation
of adult human epidermal melanocytes in vivo, resulting in increased
numbers and HMB-45 immunoreactivity of melanocytes (Grichnik
et al, 1995). Others have subsequently confirmed these findings (Costa
et al, 1996). Further, melanocytes in vitro have also been reported to
proliferate in response to SCF (Funasaka et al, 1992; Reid et al, 1995).
Although no specific inhibition of human melanocytes has been
reported in vivo, KIT anti-sense oligonucleotides decrease proliferation
of cultured human melanocytes in vitro (Spritz, 1994). These findings
suggest that the SCF pathway may have a continuing influence on
melanocytes, not limited to events during development.
In order to explore the potential role of the SCF/KIT pathway in
the control of normal cutaneous melanocyte homeostasis, we have
performed intracutaneous injections of SCF or KIT-inhibitory antibody
(K44.2, Blechman et al, 1993, 1995) into xenografts of normal human
skin. This system is advantageous because it allows for the in vivo study
of these agents on human melanocytes, within an intact cutaneous
cellular environment, but without potential associated patient risks.
Further, human SCF, while activating the human KIT receptor, does
not activate the murine KIT receptor (Matous et al, 1996) and the
K44.2 is a mouse monoclonal antibody against the human KIT receptor
without known activity against the murine Kit receptor. Thus possible
influences from the murine humoral or murine cellular system in
response to the human SCF or K44.2 antibody are minimized.
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Figure 1. SCF injection results in an apparent increase in melanocyte
size. Photomicrographs of hematoxylin and eosin of formalin-fixed xenografted
tissue are shown. (a) PBS-treated tissue revealing the presence of normal-
appearing melanocytes. (b) Two microgram SCF-injected tissue revealing
enlarged melanocytes with abundant cytoplasm. Scale bar, 50 µm.
Using this model, in this report we demonstrate that the SCF/KIT
pathway is functional in adult human skin. Pharmacologic modulation
of this pathway within the cutaneous environment suggests that it plays
a critical role in the control of human melanocyte homeostasis.
MATERIALS AND METHODS
Human skin xenografting All experiments were conducted with the
approval of the animal use and care committee. NIH-III mice (nude, beige,
and x-linked immunodeficient) were purchased from Charles River Labs
(Wilmington, MA). Human skin was obtained as residual tissue from plastic
surgery procedures from five fair-skinned patients, and grossly lacked pigmentary
abnormalities. The tissue was stored at 4°C in Dulbecco’s minimal essential
medium, supplemented with 10% fetal bovine serum, Gentamicin, and
Fungizone (Life Technologies, Grand Island, NY) and grafted within 24 h of
procurement. Prior to all surgical procedures, mice were anesthetized by
intraperitoneal injection of 90 mg ketamine (Aveco, Fort Dodge, IA) per kg
and 10 mg xylazine (Haver, Shawnee, KS) per kg. The graft was placed on a
glass coverslip, and inserted dermis-down into a flank incision; the wound was
sutured and dressed with polysporin ointment. After 21–35 d, the graft was
exposed by excising the overlying mouse skin and removing the coverslip. The
Figure 2. SCF injection results in an increase in the number of
identifiable melanocytes. Human skin xenografts were injected with four
once-daily injections of 0.2 µg SCF, 2.0 µg SCF, or PBS. The xenografts were
harvested 2–4 h after the last injection and processed for routine hematoxylin
and eosin and immunohistology with HMB45, NKI/beteb, and Mel-5. The
first and second experiments included xenografts injected with PBS, 0.2 µg
SCF, and 2.0 µg SCF, whereas the third experiment included xenograft-injected
PBS, and two different sources of 2.0 µg SCF. The hematoxylin and eosin and
immunostained specimens of each injection for all three experiments were
evaluated and the data expressed as the cell numbers per 0.5 mm epidermal
length (mean 6 SEM, PBS, n 5 3, 0.2 µg SCF, n 5 2, 2.0 µg SCF, n 5 4).
Figure 3. SCF injection results in an apparent increase in the intensity
and number of melanocyte-antigen-reactive cells. The xenografted tissue
in (a) and (c) was treated with PBS whereas that in (b) and (d) was treated with
2.0 µg SCF. Immunohistochemical staining with HMB-45 on formalin-fixed
paraffin-embedded tissue is shown in (a) and (b). Immunohistochemical staining
of frozen section with Mel-5 is demonstrated in (c) and (d). Scale bar, 50 µm.
grafts were allowed to mature for 6–13 wk, until the surfaces of the grafts were
smooth and without scale. After treatment, the grafts and adjacent mouse skin
were excised, frozen in embedding medium, or fixed in formalin, processed,
and embedded in paraffin.
Injection procedure The treatment agents or phosphate-buffered saline
(PBS) (negative control) were injected intradermally through a 3/10 ml insulin
syringe (Becton Dickinson, Franklin Lakes, NJ) into the xenografted human
tissue. Injection volumes ranged from 25 to 100 µl. Six experiments are
reported here.
In the first and second experiment, 0.2 µg and 2.0 µg of SCF were compared
with diluent. In the third experiment, two different 2.0 µg SCF preparations
[from two different sources, Peprotech and Sigma (St. Louis, MO)] were
compared with diluent. In the first experiment, 0.2 µg and 2.0 µg of SCF
(Peprotech, Rocky Hill, NJ) were dissolved in 100 µl of PBS. The volume
was reduced to 50 µl of PBS for the second experiment. In the third experiment,
the two 2.0 µg SCF preparations were diluted in 50 µl PBS. In the first three
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Table I. SCF-treated xenografts have an increased number of
melanocytes in the cell cycle compared with control PBS-
injected tissue
Experiment no. PBS SCF (2.0 µg)
1 0.3 (1/324)a 3.7 (17/457)
2 0.0 (0/225) 1.8 (8/447)
3 0.6 (5/867) 3.2 (30/950)
2.0 (17/864)b
aPercentage of melanocytes colabeling with Ki67 and Mel-5 (no. of double positive
cells/total Mel-5 positive cells).
bTwo different 2.0 µg SCF preparations were tested in experiment 3.
Figure 4. SCF treatment of xenografted tissue results in increased
melanocytes in the cell cycle. (a–f) Double-immunolabeled, SCF-injected
tissue. Mel-5 is represented in green and Ki67 is represented in red. Co-
localizing cells are yellow. Parts (a)–(c) are of a 403 field demonstrating two
cycling melanocytes. (d–f) A 1003 view of a second field demonstrating a
single positive melanocyte within a field of negative melanocytes and cycling
keratinocytes. (g–i) Different focal planes through an unusual melanocyte in the
SCF injected tissue revealing its large size and convoluted nucleus. This cell
was not Ki67 positive. Scale bars: (a–c) 50 µm; (d–i) 100 µm.
experiments, the grafts were injected with SCF or PBS daily for 4 d and
harvested 2–4 h after the fourth injection.
Murine anti-human-KIT receptor antibody (K44.2, IgG1, Sigma) was
injected at 100 µg in a 50 µl volume for experiments 4 and 5, and at
50 µg in 25 µl for experiment 6. In experiment 5, SCF (2.5 µg in 50 µl)
and nonimmune murine IgG (100 µg in 50 µl, Sigma) were also used in
addition to the PBS diluent control. The xenografted tissue was injected
daily for 3 d and harvested on day 4 in experiment 4, injected for 4 d
and harvested on day 5 in experiment 5, and injected for 8 d and harvested
on days 0, 9, and 19 for experiment 6.
Tissue processing and histologic studies Standard tissue processing and
immunohistochemical techniques were used as previously described (Grichnik
et al, 1996). For the frozen section immunohistology, monoclonal antibodies
included NKI/beteb (IgG2b, 1:50, Monosan, Uden, Netherlands), Mel-5 (clone
Ta99, IgG2a, 1:50, Signet, Dedham, MA), anti-KIT (IgG2b, 1:50, Chemicon,
Temecula, CA), and isotype-specific secondary antibodies (goat anti-mouse
IgG2a, and anti-IgG2b, Sigma). The use of the isotype-specific antibodies was
necessary to reduce background staining from endogenous murine IgG1 and
the injected K44.2 murine IgG1 antibody. The paraffin sections were reacted with
a peroxidase-conjugated HMB45 monoclonal antibody (prediluted, DAKO,
Carpinteria, CA). Histologic evaluation was conducted jointly by C.S., our
dermatopathologist, and J.G. Cells with clearly defined nuclei surrounded by a
rim of immunostain (or a rim of clear cytoplasm on the hematoxylin and eosin
stained sections) were individually counted. Assessments of antigen expression
were based on a per cell comparison with control-treated tissues processed in
an identical manner. Double immunofluorescence was also employed as
previously described (Grichnik et al, 1996). Antibodies utilized for double
immunofluorescence were Mel-5 (1:25), Ki67 (rabbit polyclonal 1:25, DAKO),
and anti-KIT (1:50). FITC-labeled anti-IgG2a and Cy3-labeled anti-rabbit IgG
(Caltag, South San Francisco, CA) were used as secondaries. Staining for
nuclear-nicked DNA ends to assess apoptosis was conducted on paraffin sections
utilizing the ApopTag kit (Oncor, Gaithersburg, MD) in accordance with the
manufacturer’s instructions.
RESULTS
SCF stimulation results in increased size, number, and
differentiation antigen expression of melanocytes No gross
change in pigmentation as a result of the four once-daily injections
of SCF was noted. Histologically, there was prominent enlargement
and an apparent increase in the number of melanocytes in the 2.0
µg injected tissue (Figs 1, 2), compared with PBS-injected
control skin. We chose to further evaluate this phenomenon
immunohistochemically. Because melanocytic antigen expression is
dynamic, with the amount of particular antigen expressed being
dependent on the local conditioning of each cell, we chose three
different antibodies, HMB45, NKI/beteb, and Mel-5. HMB 45
identifies a gp100/pmel17 epitope that is prominent on ‘‘stimulated’’
melanocytes and melanoma (Smoller et al, 1989, 1991; Adema et al,
1993). NKI/beteb identifies a gp100/pmel17 epitope present in
normal adult melanocytes (Adema et al, 1993). Mel-5 identifies
tyrosinase related protein 1 (TRP-1)/gp75 (Thomson et al, 1985;
Bouchard et al, 1994), which is encoded on a different gene from
gp100/pmel17 and therefore coordinate regulation is not necessarily
to be expected. Immunohistochemical staining of paraffin sections
revealed an increased number of HMB-45 immunoreactive cells
and a general increase in intensity of HMB-45 staining per cell in
the 2.0 µg injected tissue compared with PBS-injected controls
(Figs 2, 3a, b). Grafts injected at the 0.2 µg level had an
intermediate level of change.
Immunohistochemical studies of the frozen tissues revealed a similar
pattern. Expression of TRP-1, as detected with Mel-5 immunoreactiv-
ity, was strikingly increased in the SCF-injected specimens compared
with the PBS-injected control tissue (Fig 3c, d). The increase in
antigen intensity was prominent for the melanocyte antigens identified
by Mel-5, NKI/beteb, and HMB-45 but there also appeared to be a
general increase in the number of identifiable melanocytes (Fig 2). In
some specimens, TRP-1 staining was confluent, and the number of
reactive cells reported in Fig 2 is therefore considered a minimum
value, because of the difficulty of conclusively identifying individual
cells. NKI/beteb staining also showed an increase in identifiable cells
with SCF treatment. KIT antigenic levels were relatively low in the
xenografted tissues in these three experiments, not allowing for an
accurate quantitative assessment of cell numbers; however, further
diminution of this signal was noted in the xenografts that had been
treated with SCF.
SCF injection increases the percentage of melanocytes in the
cell cycle In order to determine whether SCF actually increased
melanocyte numbers, rather than making pre-existent melanocytes
more apparent due to increased cell size and immunoreactivity,
the percentage of melanocytes in the cell cycle was determined
immunohistochemically (Table I). By double immunofluorescence,
cycling cells were identified by Ki67, whereas melanocytes were
identified with Mel-5 (Fig 4). The fraction of cycling melanocytes in
the SCF-treated tissue was several-fold greater than in the PBS-injected
control tissue (Table I). Occasional melanocytes in the injected tissue
were large, with unusual-nuclear morphology (Fig 4g–i).
Inhibition of KIT results in decreased melanocytic antigen
expression, size, and numbers of melanocytes The K44.2-
treated tissue in the fourth experiment revealed decreased size and
number of melanocytes and markedly decreased TRP-1 staining. This
was repeated in a fifth experiment in which SCF was included in
addition to controls injected with PBS or nonimmune murine IgG
(Figs 5, 6). Hematoxylin and eosin stained sections revealed the
anticipated melanocytic enlargement and increased melanocyte numbers
in the SCF-treated tissue (Figs 5a, 6). This was in marked contrast to
the K44.2-treated tissue (Figs 5c, 6), in which only scattered, small
melanocytes could be identified. Immunohistochemical staining with
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Figure 5. KIT inhibitory antibody
treatment results in decreased
differentiation antigen expression and
loss of melanocytes. Normal human skin
xenografts were injected daily for 4 d with
50 µl of solution containing 2.5 µg SCF (a
and d), diluent PBS only (b and e), or 100 µg
K44.2 (c and f) and harvested 24 h after the
last injection. Hemayoxylin and eosin stained
sections are shown in (a)–(c). Representative
melanocytes are indicated by the white
arrows. Immunohistochemical staining with
the Mel-5 antibody against melanocyte
antigen TRP-1 is shown in (d)–(f). The PBS-
injected tissue is shown in (b) and (e), revealing
an intermediate level of melanocytic activity
that was also present in the nonimmune
murine IgG (not shown). Scale bar, 50 µm.
Figure 6. SCF increases and K44.2 decreases the apparent number of cells
positive for melanocytic differentiation antigens. Data from experiment 5
are shown. The xenografts were injected once-daily with PBS, nonimmune
murine IgG, K44.2, or SCF (2.5 µg) for 4 d. The xenografts were harvested 1
d after the last injection and processed for routine hematoxylin and eosin and
immunohistology with HMB45, Mel-5 NKI/beteb, anti-KIT. The data are
expressed as cell numbers per 0.5 mm epidermal length (mean 6 SEM, n 5 4).
the Mel-5 antibody demonstrated marked TRP-1 expression in the
SCF-treated tissue (Figs 5d, 6), whereas inhibition of the KIT receptor
with K44.2 (Figs 5f, 6) resulted in decreased staining and apparent
melanocyte loss. The PBS-injected tissue (Figs 5b, e, 6) revealed an
intermediate level of melanocytic activity consistent with that expected
of normal human skin. The nonimmune murine IgG revealed findings
similar to those in the PBS-injected tissue. KIT did not appear to be
as decreased in the SCF-injected tissue in experiment 5 to the same
extent as that detected in the earlier experiments, suggesting a degree
of recovery at 24 h as compared with that seen 2–4 h after the last
SCF injection in the prior experiments. The intensity of the KIT
expression appeared to be inversely related to the expression of the
melanocytic differentiation antigens. On day 5, although roughly
equivalent apparent KIT reactive cell numbers were seen, dramatic
shifts in differentiation antigen expression and cell size were apparent.
TUNEL labeling of K44.2-treated skin revealed rare apoptotic basal
layer cells consistent with melanocytes, but similar cells were also rarely
present in some of the other injected tissues. Immunofluorescence
evaluation of the K44.2-treated xenografts failed to reveal any cells
double-labeled with TRP-1 and Ki67, a finding suggestive of decreased
cycling of melanocytes. Due to the paucity of hematoxylin and eosin
or TRP-1 identifiable melanocytes in K44.2-injected tissue, however,
it was difficult to establish definitively whether there was a greater
percentage of apoptotic melanocytes or a decreased percentage of
cycling cells in the K44.2-treated tissue. We theorized that, if melano-
cytes were undergoing apoptosis, prolonged treatment would result in
cell loss that might not be reversible; on the other hand, if melanocytes
were merely entering a dormant or less differentiated state, they might
recover after antibody treatment was discontinued. In experiment 6, a
fragment of the graft was biopsied before treatment and demonstrated
the presence of human melanocytes (Fig 7). The graft was then treated
for 8 d with a daily 25 µl injection of K44.2. Half of the treated graft
was harvested on day 9 (1 d after the last dose of antibody) and the
other half on day 19 (11 d after the last dose). A marked drop in the
number of melanocytes was noted in both the day 9 and the day 19
specimens, with only rare melanocytes noted by either TRP-1, NKI/
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Figure 7. Prolonged K44.2 treatment results in a progressive decrease
in the apparent number of melanocytes. Data from experiment 6 are
shown. The xenograft was biopsied at day 0 prior to K44.2 injection, at day 9
(1 d after completion of eight once-daily K44.2 injections), and at day 19 (11
d after the last K44.2 injection). The xenograft samples were processed for
immunohistology with Mel-5 NKI/beteb, anti-KIT. The data are expressed as
cell numbers per 0.5 mm epidermal length (mean 6 SEM, n 5 4).
beteb, or KIT staining (Fig 7). Thus, continued exposure to the KIT
inhibitory antibody results in melanocyte loss that does not appear to
be reversible, consistent with cell death.
DISCUSSION
We have demonstrated that adult human melanocytes within human
skin xenografts respond to manipulation of the SCF/KIT pathway by
alteration of both proliferation and differentiation characteristics. These
are rather remarkable functions for a single pathway but this dual
function is consistent with effects reported for other cell systems
including hematopoietic stem cells (Dai et al, 1991), mast cells (Tsai
et al, 1991), and germ cells (Manova et al, 1993).
SCF/KIT activation increased expression of the melanocytic differen-
tiation antigens TRP-1 and gp100/pmel17, and conversely KIT
inhibition markedly decreased this expression. Because these antigens
are implicated in pathways of melanogenesis, this modulation suggests
that KIT activation directly affected the critical physiologic function
of melanocytes. Melanocyte volume also appeared to increase as a
result of SCF stimulation. Interestingly, KIT expression, which we
have previously reported to be present on putative quiescent or
‘‘precursor’’ melanocytes (Grichnik et al, 1996), appeared to be inversely
correlated with the state of SCF/KIT activation, i.e., SCF-treated
tissues revealed decreased KIT staining and K44.2-treated specimens
showed increased expression. In mast cells, KIT appears to be internal-
ized and degraded after activation by SCF; new expression of the
receptor appears to require new synthesis (Shimizu et al, 1991). Our
results are consistent with negative regulation of KIT expression by
activation of this pathway in melanocytes. The melanocytes in the
K44.2-treated tissue had markedly decreased TRP-1 expression, sug-
gesting that blockade of the SCF-KIT pathway can inhibit melanization
in differentiated melanocytes. Melanoma cell lines in which KIT is
downregulated are often amelanotic and have lost TRP-1 activity (Luo
et al, 1995). Similarly, a melanoma cell line developed from a murine
strain homozygous for a mild Kit defect (Wf) is amelanotic (Larue et al,
1992). Conversely, SCF treatment of KIT-positive melanoma lines
results in a transient increase in DOPA-oxidase activity, suggesting
increased melanization capability (Luo et al, 1995). The capacity of
SCF/KIT activation to drive melanogenesis is also supported by the
human studies, in which skin locally injected with SCF revealed
increased melanin and HMB-45 activity (Grichnik et al, 1995). Taken
together, these data suggest that the SCF/KIT pathway can regulate
melanization and that this pathway is functional in xenografted
human skin.
SCF has been reported to drive the proliferation of murine melano-
cyte precursors (Reid et al, 1995), and in the presence of dbcAMP or
TPA to induce proliferation of human melanocytes in vitro (Funasaka
et al, 1992). In an effort to specifically assess the effect of SCF on
proliferation, we evaluated the percentage of melanocytes in the cell
cycle as defined by Ki67 expression. The number of cycling melanocytes
in SCF-treated xenografts was modest (2–3%), but was several-fold
more than in control tissue. For comparison, the epidermal melanocytes
of common nevus, atypical nevus, and Spitz’s nevus are reported to
have 0.31%, 0.67%, and 1.76% Ki671 cells, respectively, whereas
epidermal melanoma cells show a proliferative index of 6.4%, 10.25%,
and 13.25% for in situ, thin (,0.8 mm), and not as thin (.0.8 mm)
tumors, respectively (Ki-S5 antibody, Rudolph et al, 1995). Thus
treatment with 2.0 µg SCF for 4 d resulted in melanocytic proliferation
at a level comparable with that reported for Spitz’s nevus but somewhat
less than melanoma in situ.
Published experiments utilizing ACK2, a specific blocking antibody
of SCF activation of Kit (Nishikawa et al, 1991), have demonstrated
the crucial role of the SCF/Kit pathway for developing murine
melanocytes. ACK2 treatment leads to the loss of melanocytes at
specific developmental time points, when melanocytes are migrating
through the dermis, entering the epidermis, or populating the hair
follicles (Yoshida et al, 1996). ACK2 inhibition of the Kit receptor
appears to result in melanocyte apoptosis (Okura et al, 1995). Similarly,
our experiments indicate that adult human epidermal melanocytes are
quite sensitive to inhibition induced by the K44.2 antibody. The
residual human melanocytes within the tissue treated for 4 d with anti-
KIT (experiment 5) had small cytoplasmic and nuclear volumes and
markedly decreased dendritic processes. After daily treatment for 8 d
and an 11 d recovery period, detectable melanocytes remained rare.
The mechanism by which this loss occurred seems consistent with
apoptosis; however, further studies will be necessary to sort out the
specific processes involved in the induction of human melanocyte loss
by K44.2.
Our findings suggest that the SCF/KIT pathway may function as a
primary mechanism for regulating both proliferation and differentiation
of melanocytes. The compartmentalization of this pathway is highly
suitable for the homeostatic function of providing protective melanin
to the epidermis. SCF on the cell surface of epidermal keratinocytes
may permit regulation of adjacent melanocytes within the epidermal
compartment, via direct interaction with the melanocyte’s KIT receptor.
This system may operate in a manner similar to that demonstrated in
the testis, where follicle stimulating hormone stimulates the production
of SCF by the Leydig cell (Rossi et al, 1993), in turn supporting the
proliferation of KIT-expressing spermatogonia (Manova et al, 1993).
This type of control mechanism may allow for tight control of cell
types with high proliferative potential, which may include melanocytes
within human skin.
Because the SCF/KIT pathway is important for normal melanocytic
function, it is possible that alterations of the pathway are responsible
for some melanocytic disease processes. Autocrine SCF stimulation of
the KIT receptor is an attractive potential mechanism for driving
melanocyte proliferation in early melanoma, as has been proposed for
several hematologic and solid tumors (Hibi et al, 1991; Berdel et al,
1992; Sekido et al, 1993; Longley et al, 1993; Kiss et al, 1993; Cohen
et al, 1994; Nagata et al, 1995). Downregulation of KIT has been
reported in the later stages of melanoma (Natali et al, 1992; Lassam
and Bickford, 1992; Mattei et al, 1994; Takahashi et al, 1995; Ohashi
et al, 1996; Zakut et al, 1993), however, and might permit escape from
KIT growth control or, by reducing the expression of differentiation
antigens, might allow melanoma cells to evade immunosurveillance.
Further research is necessary to decipher the role of the SCF-KIT
pathway in melanocytic proliferative processes as well as its role
during the early and later stages of melanoma progression. Future
pharmacologic therapies based on activation or inhibition of this
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pathway may present new treatment options for the treatment of
melanocytic disease processes.
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